|Day Low/High||5.07 / 5.21|
|52 Wk Low/High||3.36 / 9.25|
The market is in no mood to give the benefit of the doubt to a stock acting as poorly as Facebook.
Big-cap FAANG names and Apple, in particular, were the beneficiaries.
For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'
The satellite radio operator's stock is declining after announcing the purchase of the streaming radio service.
Stock buyers are back after Thursdays selloff helped by Pandora's jump higher. Dell's disaster continues and China has a fat finger trade.
A growing and aging population ensures biotechs won't go out of style.
US stock futures are rising on strong earnings from DuPont and Coach, while Amarin gets a nod from the FDA - Debra Borchardt gives details.
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Be willing to chase this rally, even though it's disliked by so many market players.
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.
Adam Feuerstein, senior columnist for TheStreet, says Amarin and Onyx are the next big things in biotech.
Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Tibco Software, Arena Pharma, and Church & Dwight.
After AAP and ORLY warn, one has to be very cautious with Autozone.
The downtrend isn't over yet, so you might as well knock out some trades in the short term.
Market strength on May 1 is not necessarily an indication that a rally will follow.
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
After its recent run, it appears to be headed for its next price target.
The only big move was a stumble in volatility, but equities failed to take advantage.